Since we began our drug-discovery and development activities in early 2002, we have filed Investigational New Drug applications and progressed multiple internally developed proprietary compounds into clinical development.

Our core competency in medicinal chemistry, which is tightly integrated with and supported by an experienced team of biologists with expertise in multiple therapeutic areas, has been a primary driver of our productivity in drug discovery. As a number of our compounds have progressed into human trials, we have also built a clinical development and regulatory team. This team taps into clinical research organizations, expert scientific advisory boards, and leading consultants and suppliers in relevant drug development areas in an effort to conduct our clinical trials as efficiently and effectively as possible while maintaining strategic control of the design and management of our programs. Our lead product, Jakafi™(ruxolitinib), a JAK1 and JAK2 inhibitor, is approved in the United States for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers.